Literature DB >> 17827723

Monovalent Gb3-/Gb2-derivatives conjugated with a phosphatidyl residue: a novel class of Shiga toxin-neutralizing agent.

Paola Neri1, Shunji Tokoro, Shin-Ichiro Yokoyama, Tsuyoshi Miura, Takeomi Murata, Yoshihiro Nishida, Tetsuya Kajimoto, Satoshi Tsujino, Toshiyuki Inazu, Taiichi Usui, Hiroshi Mori.   

Abstract

Shiga toxin (Stx) exerts toxic activity by binding to glycosphingolipids, mainly globotriaosyl (Gb(3)) ceramide, on the surface of target cells. The inhibition of toxin-receptor binding is a promising therapeutic approach to prevent Stx-mediated diseases. In this study, we synthesized monovalent Stx-ligands of phosphatidylethanolamine dipalmitoyl-Gb(3) (Gb(3)-PEDP) and galabiosyl (Gb(2))-PEDP and we examined their neutralizing activity against Stx-1 and Stx-2 in vitro. Both Gb(3)-PEDP and Gb(2)-PEDP strongly neutralized the cytotoxicity of Stx-1 and Stx-2. It is likely that the mechanism of neutralization involved formation of liposomes and consequently clustering of sugar units. We propose monovalent Gb(3)-/Gb(2)-derivatives conjugated with phosphatidyl residue as a novel class of Stx-neutralizing agent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827723     DOI: 10.1248/bpb.30.1697

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  4 in total

1.  In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins.

Authors:  Pavel I Kitov; George L Mulvey; Thomas P Griener; Tomasz Lipinski; Dmitry Solomon; Eugenia Paszkiewicz; Jared M Jacobson; Joanna M Sadowska; Missao Suzuki; Ken-Ichi Yamamura; Glen D Armstrong; David R Bundle
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

2.  Specific egg yolk immunoglobulin as a new preventive approach for Shiga-toxin-mediated diseases.

Authors:  Paola Neri; Shunji Tokoro; Ryo Kobayashi; Tsuyoshi Sugiyama; Kouji Umeda; Takeshi Shimizu; Takao Tsuji; Yoshikatsu Kodama; Keiji Oguma; Hiroshi Mori
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

Review 3.  Verotoxin Receptor-Based Pathology and Therapies.

Authors:  Clifford Lingwood
Journal:  Front Cell Infect Microbiol       Date:  2020-03-31       Impact factor: 5.293

4.  A small bioactive glycoside inhibits epsilon toxin and prevents cell death.

Authors:  Abhishek Shivappagowdar; Soumya Pati; Chintam Narayana; Rajagopal Ayana; Himani Kaushik; Raj Sah; Swati Garg; Ashish Khanna; Jyoti Kumari; Lalit Garg; Ram Sagar; Shailja Singh
Journal:  Dis Model Mech       Date:  2019-10-10       Impact factor: 5.758

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.